Loading...

PE/Cyanine5 anti-mouse CD8a Antibody PE/Cyanine5 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-67_PECyanine5_CD8a_Antibody_1_071324
C57BL/6 mouse splenocytes were stained with anti-mouse CD3ε (clone 145-2C11) FITC and anti-mouse CD8a (clone 53-6.7) PE/Cyanine5 (left) or rat IgG2a, κ PE/Cyanine5 isotype control (right).
  • 53-67_PECyanine5_CD8a_Antibody_1_071324
    C57BL/6 mouse splenocytes were stained with anti-mouse CD3ε (clone 145-2C11) FITC and anti-mouse CD8a (clone 53-6.7) PE/Cyanine5 (left) or rat IgG2a, κ PE/Cyanine5 isotype control (right).
Compare all formats See PE/Cyanine5 spectral data
Cat # Size Price Quantity Check Availability Save
100709 25 µg DKK458
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100710 100 µg DKK1177
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.04 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Erickson JJ, et al. 2022. Nature. 606:769. PubMed
  2. Campisi L, et al. 2022. Nature. 606:945. PubMed
  3. Phares TW, et al. 2022. Front Pharmacol. 13:1029636. PubMed
  4. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  5. Wang L, et al. 2023. Oxid Med Cell Longev. 2023:6480848. PubMed
  6. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  7. Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed
  8. Wang Z, et al. 2023. J Cancer. 14:1049. PubMed
  9. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  10. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  11. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  12. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  13. Hofmann I, et al. 2022. J Pharmacol Exp Ther. Online ahead of print. PubMed
  14. Karagiannidis I, et al. 2020. Front Immunol. 11:1885. PubMed
  15. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  16. Ihara S, et al. 2022. PLoS Negl Trop Dis. 16:e0010323. PubMed
  17. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  18. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  19. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  20. Sharma PK, et al. 2018. Cancer Gene Ther. 25:27. PubMed
  21. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  22. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  23. Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed
  24. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  25. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  26. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  27. Wachsmuth LP, et al. 2020. Biol Blood Marrow Transplant. 26:230. PubMed
  28. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  29. Yankova E, et al. 2021. Nature. 593:597. PubMed
  30. Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed
  31. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  32. Ma P, et al. 2014. Diabetes. 63:3458. PubMed
  33. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  34. Sim S, et al. 2016. PLoS One. 11: 0152485. PubMed
  35. Yang R, et al. 2022. J Adv Res. 35:259. PubMed
  36. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  37. Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed
  38. XS R, et al. 2015. Diabetes. 64 90. PubMed
  39. Naik A, et al. 2015. J Immunol. 194:790. PubMed
  40. Todd D, et al. 2009. J Exp Med. 206:2151. PubMed
  41. Edwards-Hicks J, et al. 2020. Metabolites. 11:. PubMed
  42. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  43. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  44. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  45. Di Genua C, et al. 2019. Haematologica. 104:2215. PubMed
  46. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  47. Tzelepis K, et al. 2018. Nat Commun. 9:5378. PubMed
  48. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  49. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  50. Lo W, et al. 2014. Elife. 14:1457. PubMed
  51. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  52. Chavez JS, et al. 2022. Cells. 11:. PubMed
  53. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  54. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  55. Gozdecka M, et al. 2018. Nat Genet. 50:883. PubMed
  56. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  57. Erickson JJ, et al. 2022. Nature. 606:769. PubMed
  58. Campisi L, et al. 2022. Nature. 606:945. PubMed
  59. Phares TW, et al. 2022. Front Pharmacol. 13:1029636. PubMed
  60. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  61. Wang L, et al. 2023. Oxid Med Cell Longev. 2023:6480848. PubMed
  62. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  63. Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed
  64. Wang Z, et al. 2023. J Cancer. 14:1049. PubMed
  65. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  66. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  67. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  68. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  69. Hofmann I, et al. 2022. J Pharmacol Exp Ther. Online ahead of print. PubMed
  70. Karagiannidis I, et al. 2020. Front Immunol. 11:1885. PubMed
  71. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  72. Ihara S, et al. 2022. PLoS Negl Trop Dis. 16:e0010323. PubMed
  73. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  74. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  75. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  76. Sharma PK, et al. 2018. Cancer Gene Ther. 25:27. PubMed
  77. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  78. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  79. Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed
  80. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  81. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  82. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  83. Wachsmuth LP, et al. 2020. Biol Blood Marrow Transplant. 26:230. PubMed
  84. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  85. Yankova E, et al. 2021. Nature. 593:597. PubMed
  86. Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed
  87. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  88. Ma P, et al. 2014. Diabetes. 63:3458. PubMed
  89. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  90. Sim S, et al. 2016. PLoS One. 11: 0152485. PubMed
  91. Yang R, et al. 2022. J Adv Res. 35:259. PubMed
  92. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  93. Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed
  94. XS R, et al. 2015. Diabetes. 64 90. PubMed
  95. Naik A, et al. 2015. J Immunol. 194:790. PubMed
  96. Todd D, et al. 2009. J Exp Med. 206:2151. PubMed
  97. Edwards-Hicks J, et al. 2020. Metabolites. 11:. PubMed
  98. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  99. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  100. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  101. Di Genua C, et al. 2019. Haematologica. 104:2215. PubMed
  102. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  103. Tzelepis K, et al. 2018. Nat Commun. 9:5378. PubMed
  104. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  105. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  106. Lo W, et al. 2014. Elife. 14:1457. PubMed
  107. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  108. Chavez JS, et al. 2022. Cells. 11:. PubMed
  109. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  110. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  111. Gozdecka M, et al. 2018. Nat Genet. 50:883. PubMed
  112. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
RRID
AB_312748 (BioLegend Cat. No. 100709)
AB_312749 (BioLegend Cat. No. 100710)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
StarBright UltraViolet 575 anti-mouse CD8a 53-6.7 FC
Spark YG™ 581 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark YG™ 593 anti-mouse CD8a (Flexi-Fluor™) Antibody 53-6.7 FC
StarBright UltraViolet 795 anti-mouse CD8a 53-6.7 FC
Spark PLUS V475™ anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 09/18/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-67_PECyanine5_CD8a_Antibody_1_071324
C57BL/6 mouse splenocytes were stained with anti-mouse CD3ε (clone 145-2C11) FITC and anti-mouse CD8a (clone 53-6.7) PE/Cyanine5 (left) or rat IgG2a, κ PE/Cyanine5 isotype control (right).
  • 53-67_PECyanine5_CD8a_Antibody_1_071324
    C57BL/6 mouse splenocytes were stained with anti-mouse CD3ε (clone 145-2C11) FITC and anti-mouse CD8a (clone 53-6.7) PE/Cyanine5 (left) or rat IgG2a, κ PE/Cyanine5 isotype control (right).
Compare all formats See PE/Cyanine5 spectral data
Cat # Size Price Quantity Check Availability Save
100709 25 µg DKK458
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100710 100 µg DKK1177
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.04 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Erickson JJ, et al. 2022. Nature. 606:769. PubMed
  2. Campisi L, et al. 2022. Nature. 606:945. PubMed
  3. Phares TW, et al. 2022. Front Pharmacol. 13:1029636. PubMed
  4. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  5. Wang L, et al. 2023. Oxid Med Cell Longev. 2023:6480848. PubMed
  6. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  7. Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed
  8. Wang Z, et al. 2023. J Cancer. 14:1049. PubMed
  9. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  10. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  11. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  12. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  13. Hofmann I, et al. 2022. J Pharmacol Exp Ther. Online ahead of print. PubMed
  14. Karagiannidis I, et al. 2020. Front Immunol. 11:1885. PubMed
  15. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  16. Ihara S, et al. 2022. PLoS Negl Trop Dis. 16:e0010323. PubMed
  17. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  18. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  19. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  20. Sharma PK, et al. 2018. Cancer Gene Ther. 25:27. PubMed
  21. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  22. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  23. Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed
  24. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  25. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  26. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  27. Wachsmuth LP, et al. 2020. Biol Blood Marrow Transplant. 26:230. PubMed
  28. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  29. Yankova E, et al. 2021. Nature. 593:597. PubMed
  30. Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed
  31. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  32. Ma P, et al. 2014. Diabetes. 63:3458. PubMed
  33. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  34. Sim S, et al. 2016. PLoS One. 11: 0152485. PubMed
  35. Yang R, et al. 2022. J Adv Res. 35:259. PubMed
  36. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  37. Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed
  38. XS R, et al. 2015. Diabetes. 64 90. PubMed
  39. Naik A, et al. 2015. J Immunol. 194:790. PubMed
  40. Todd D, et al. 2009. J Exp Med. 206:2151. PubMed
  41. Edwards-Hicks J, et al. 2020. Metabolites. 11:. PubMed
  42. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  43. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  44. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  45. Di Genua C, et al. 2019. Haematologica. 104:2215. PubMed
  46. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  47. Tzelepis K, et al. 2018. Nat Commun. 9:5378. PubMed
  48. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  49. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  50. Lo W, et al. 2014. Elife. 14:1457. PubMed
  51. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  52. Chavez JS, et al. 2022. Cells. 11:. PubMed
  53. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  54. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  55. Gozdecka M, et al. 2018. Nat Genet. 50:883. PubMed
  56. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  57. Erickson JJ, et al. 2022. Nature. 606:769. PubMed
  58. Campisi L, et al. 2022. Nature. 606:945. PubMed
  59. Phares TW, et al. 2022. Front Pharmacol. 13:1029636. PubMed
  60. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  61. Wang L, et al. 2023. Oxid Med Cell Longev. 2023:6480848. PubMed
  62. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  63. Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed
  64. Wang Z, et al. 2023. J Cancer. 14:1049. PubMed
  65. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  66. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  67. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  68. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  69. Hofmann I, et al. 2022. J Pharmacol Exp Ther. Online ahead of print. PubMed
  70. Karagiannidis I, et al. 2020. Front Immunol. 11:1885. PubMed
  71. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  72. Ihara S, et al. 2022. PLoS Negl Trop Dis. 16:e0010323. PubMed
  73. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  74. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  75. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  76. Sharma PK, et al. 2018. Cancer Gene Ther. 25:27. PubMed
  77. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  78. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  79. Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed
  80. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  81. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  82. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  83. Wachsmuth LP, et al. 2020. Biol Blood Marrow Transplant. 26:230. PubMed
  84. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  85. Yankova E, et al. 2021. Nature. 593:597. PubMed
  86. Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed
  87. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  88. Ma P, et al. 2014. Diabetes. 63:3458. PubMed
  89. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  90. Sim S, et al. 2016. PLoS One. 11: 0152485. PubMed
  91. Yang R, et al. 2022. J Adv Res. 35:259. PubMed
  92. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  93. Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed
  94. XS R, et al. 2015. Diabetes. 64 90. PubMed
  95. Naik A, et al. 2015. J Immunol. 194:790. PubMed
  96. Todd D, et al. 2009. J Exp Med. 206:2151. PubMed
  97. Edwards-Hicks J, et al. 2020. Metabolites. 11:. PubMed
  98. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  99. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  100. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  101. Di Genua C, et al. 2019. Haematologica. 104:2215. PubMed
  102. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  103. Tzelepis K, et al. 2018. Nat Commun. 9:5378. PubMed
  104. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  105. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  106. Lo W, et al. 2014. Elife. 14:1457. PubMed
  107. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  108. Chavez JS, et al. 2022. Cells. 11:. PubMed
  109. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  110. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  111. Gozdecka M, et al. 2018. Nat Genet. 50:883. PubMed
  112. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
RRID
AB_312748 (BioLegend Cat. No. 100709)
AB_312749 (BioLegend Cat. No. 100710)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
StarBright UltraViolet 575 anti-mouse CD8a 53-6.7 FC
Spark YG™ 581 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark YG™ 593 anti-mouse CD8a (Flexi-Fluor™) Antibody 53-6.7 FC
StarBright UltraViolet 795 anti-mouse CD8a 53-6.7 FC
Spark PLUS V475™ anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 09/18/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account